[{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sedana Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Sedaconda (isoflurane) is an inhalation anesthetic that acts as a GABAA receptor modulator, decreasing motor function and inhibiting excitatory neurotransmission via NMDA receptors.

                          Brand Name : Sedaconda ACD

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 25, 2024

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Sedaconda (isoflurane), a general inhalation anesthetic, acts as a positive allosteric GABAA receptor modulator. It enhances glycine receptor activity, which decreases motor function and inhibits NMDA glutamate receptor, which mediates excitatory neurotr...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 04, 2023

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Company received IND clearance from the USFDA to initiate phase III pivotal clinical trials with its combination registration of medical device Sedaconda ACD and pharmaceutical Sedaconda (isoflurane) for sedation of mechanically ventilated intensive care...

                          Brand Name : Sedaconda

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 23, 2021

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Sedaconda (isoflurane) for inhaled sedation used in combination with medical device Sedaconda ACD, it's primary endpoint in each study will is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care u...

                          Brand Name : Sedaconda

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 24, 2021

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.

                          Brand Name : Sedaconda

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 20, 2021

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The results indicate that IsoConDa is an effective and safe sedation method and will form the basis for the company's application for European market approval later this autumn.

                          Brand Name : IsoConDa

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 10, 2020

                          Lead Product(s) : Isoflurane

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank